


ESMÉ



THE UNICANCER REAL WORLD DATA PROGRAM

ACQUIRING, ENHANCING AND CENTRALIZING EXISTING REAL WORD DATA IN ONCOLOGY

In 2014, Unicancer launched the Epidemiological Strategy and Medical Economics (ESME) Research program to centralize existing real world oncology patient data in one unique Data Platform. **This independant platform provides high quality aggregated data, available to the scientific and medical community for analysis (via recurrent requests for proposals), and to the pharmaceutical industry and health authority in the form of statistical reports.** So far, data contributors include the Unicancer network of comprehensive cancer centres, and public and private hospitals across France. The Unicancer Real World Data Platform is supported by six major partners and its developments and uses are closely discussed with health authorities.



*2018 figures

Strategic priorities:

- Retrospectively describe the therapeutic management and characteristics of French cancer patients
- Describe the current standard therapeutic strategies and treatment lines
- Describe reported outcomes that tend to influence the therapeutic strategies
- Provide data to support Health Economic Models and requirements from Health Authorities
- Provide data for market access filing, e.g. target population, cost-effectiveness

50,000

cases available in the three ESME databases

8

years of follow-up (up to)

26

communications and publications in major international congresses

ESME Research Data Platform: source of the collected data

Patient Database



Treatment Database



Hospital Database



ESME Data platform

Data administration using a "Certified personal health data hosting" provider

Patient Database

> Patient data collected from electronic health records

> Demographics, cancer management, clinical events, pathological reports, metastatic disease, anticancer treatment and other therapeutic care

Treatment Database

> Pharmacy records; Dates, cytotoxic drugs, therapeutic protocols and other concomitant drugs

Hospital Database

> Hospitalizations (dates, diagnoses, standardized code)

> Medical procedures (including Radiotherapy): dates and code



ESME ADVANCED & METASTATIC LUNG CANCER

Evaluate the impact of new therapies, especially immunotherapies, on metastatic lung cancer

The aim of this project is to build a comprehensive data platform describing the evolution of medical care for patients treated for an advanced or metastatic lung cancer (clinical and pathological features, treatment, survival outcomes) across the FCCC network as well as in public and private hospitals in France.

With this data platform, it will be possible to evaluate the impact of new therapies, especially immunotherapies, on the treatment of advanced and metastatic lung cancer.

Objective:

- > 26 000 cases available by 2021
- > First medical care for the metastatic disease : 2015 to 2020
- > Annual updates for all patients
- > 36 sites: 18 FCCCs / 18 General or University Hospitals



18,000
cases selected



28
active sites and 6 other
activated by end 2019



More than
50%
of cases expected from
non-FCCC sources in 2019

Director of Real Data World Department

Mathieu Robain
m-robain@unicancer.fr

Manager of operations Data Management

Coralie Courtinard
c-courtinard@unicancer.fr

Development, partnership and strategic alliance Director :

Anne-Laure Martin
al-martin@unicancer.fr

Scientific Group President:

David Perol
david.perol@lyon.unicancer.fr

>>> For more information : www.unicancer.fr/en/esme